Nemaura Pharma today announced it has entered in to a collaboration with a multinational Pharmaceutical Company to advance multiple complex injectable products that Nemaura has developed over period of several years. As part of the agreement the partner company will co-fund and undertake all aspects of manufacture scale-up, exhibit batch manufacture, and commercial supply of both terminally sterilised as well as aseptically manufactured complex injectable medicines that have been developed by Nemaura. The total addressable market targeted by these medicines exceeds $4Billion. Dr Faz Chowdhury, CEO of Nemaura Pharma Limited stated “after over a year of negotiations we are delighted to have entered in to this large scale collaboration for our range of complex medicines, and with our combined complementary skills in product development and Commercial scale manufacture we believe we have struck the ideal partnership and one that will allow us to progress these medicines to registration and sale in major global territories”.
Menu